Joe Blanchard, M.B.A.
CO-FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Mr. Blanchard has co-founded and has been a member of the leadership teams that helped build several life science companies. In addition to Amorsa, Mr. Blanchard also co-founded and has served as CEO of NeurAegis, Inc., a company developing novel treatments for neurological disorders including traumatic brain injury. He also co-founded and served as Chief Operating Officer at Aushon BioSystems (acquired by Quanterix in 2018), a life sciences instrumentation company.
Mr. Blanchard was also an early member of the leadership team for Altus Pharmaceuticals (a spin-out of Vertex Pharmaceuticals and 2006 IPO), where he held several senior management positions. Prior to Altus, he was Director of Sales Operations (The Americas) for Genencor International (2000 IPO; now owned by DuPont), where he led a 40-member commercial team generating over $130 million annually.
Mr. Blanchard was also Senior Vice President, Business Development at Decision Biomarkers and earlier in his career held business unit and sales management positions with Akzo Nobel of the Netherlands and DuPont/Conoco Chemicals. He has an M.B.A and B.S. degree from Miami University.
Alex Nivorozhkin, Ph.D.
CO-FOUNDER, MEDICINAL CHEMISTRY
Dr. Nivorozhkin is a co-inventor of several drug candidates that have advanced to clinical trials, has co-authored over 60 scientific publications in different areas of chemistry, chemical biology, and material sciences and holds more than 20 patents. He received a Ph.D. in Physical Organic Chemistry from Rostov University and conducted his postdoctoral research at the University Paris-Sud, France, and the Department of Chemistry and Chemical Biology, Harvard University.
Michael Palfreyman, DSc., Ph.D.
CO-FOUNDER, PRECLINICAL DRUG DEVELOPMENT
Dr. Palfreyman is an internationally recognized leader in drug development with a successful scientific and business career spanning 35 years. He brings to Amorsa a distinguished track record of successful drug development and considerable expertise in CNS pharmacology, pharmacogenomics and rational drug design.
Dr. Palfreyman’s broad perspective on drug development derives from his experience as founder, President and CSO of Psychiatric Genomics; Senior Scientific Advisor to EnVivo Pharmaceuticals and Vitruvean; co-founder of NOVACE; Senior VP for Research and Development at Anadys (formerly Scriptgen); as well as senior executive and scientific leadership roles at Marion Merrell Dow (Sanofi-Aventis) and Beecham (GlaxoSmithKline). In these roles, he successfully developed and demonstrated clinical efficacy of several candidates across multiple therapeutic areas.
Dr. Palfreyman holds Ph.D. and D.Sc. degrees and is a member of the Royal Pharmaceutical Society. He continues to be an active scientific contributor with more than 150 publications and 35 issued patents.